Company profile
VIATRIS INC
NASDAQ:VTRSBiotechnology: Pharmaceutical Preparations
Drug pipeline (378)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NORVASC | approved | $200.2MQ2 2026 | 14 | approved |
| EPIPEN | approved | $129.2MQ2 2026 | 1 | approved |
| VIAGRA | approved | $112.9MQ2 2026 | 25 | approved |
| ZOLOFT | approved | $71.4MQ2 2026 | 5 | approved |
| YUPELRI | approved | $70.7MQ2 2026 | 1 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (558)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00159757 | phase4 | terminated | 2003-11-01 | — | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients |
| NCT01061372 | phase3 | withdrawn | 2010-05-01 | 2011-08-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects |
| NCT00312494 | phase3 | completed | 2006-04-01 | 2008-12-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects |
| NCT00739999 | phase1 | completed | 2008-12-01 | 2009-05-01 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia |
| NCT01463306 | phase3 | completed | 2012-02-21 | 2019-08-22 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures |
FDA applications (483)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| ANDA 213915 | 2026-07-28 | ANDA | MYLAN PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| NDA 219990 | 2026-07-28 | NDA | VIATRIS SPECIALITY LLC | |||||
Loading… | ||||||||
| ANDA 212572 | 2026-06-25 | ANDA | MYLAN LABORATORIES LTD | |||||
Loading… | ||||||||
| ANDA 217076 | 2026-06-25 | ANDA | MYLAN PHARMACEUTICALS INC | |||||
Loading… | ||||||||
| ANDA 217769 | 2026-06-25 | ANDA | MYLAN PHARMACEUTICALS INC | |||||
Loading… | ||||||||